CMS Announces Billing Change for COVID-19 Vaccine & Monoclonal Antibody Products for MA Plan Beneficiaries
By: Kathie McDonald-McClure
Centers for Medicare & Medicaid Services (CMS) changed the Medicare payment policy for COVID-19 vaccines and monoclonal antibody products effective January 1, 2022. According to the CMS MLN Connects News for January 6, 2022, providers who administer COVID-19 vaccinations or monoclonal antibody treatments to patients enrolled in Medicare Advantage (MA) plans (as opposed to Original Medicare) are to submit claims to the MA Plan. This change applies to COVID-19 vaccinations and monoclonal antibody treatments administrated on or after January 1, 2022. CMS states that Original Medicare will not pay these claims.
For additional information regarding COVID-19 vaccination billing, visit the CMS webpage Medicare Billing for COVID-19 Vaccine Shot Administration.
For additional information regarding monoclonal antibody treatment billing, visit the CMS webpage Monoclonal COVID-19 Infusion.